Clinical trials: Idiopathic Gastroparesis
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Diabetic Gastroparesis
Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant
- Trial name
- NCT04474990
- Testing
- Tradipitant
- Where
- 15 sites in United States
- Sponsor
- Vanda Pharmaceuticals
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
- Trial name
- NCT03544229
- Testing
- TAK-906 Maleate
- Where
- 109 sites in United States, Belgium and 2 more
- Volunteers
- 242 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
- Trial name
- NCT03268941
- Testing
- TAK-906 Maleate, Metaclopramide
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.
- Trial name
- NCT04303195
- Testing
- NG101
- Where
- 83 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurogastrx, Inc.
Gastroparesis
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study.
- Trial name
- NCT01718938
- Testing
- velusetrag dose 1, velusetrag dose 2, velusetrag dose 3
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Gastroparesis
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
Study 0099 explores the efficacy and safety of multiple doses of velusetrag in the treatment of symptoms in subjects with diabetic or idiopathic gastroparesis.
- Trial name
- DIGEST (NCT02267525)
- Testing
- Velusetrag
- Volunteers
- 233 people
- Sponsor
- Theravance Biopharma
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Diabetic Gastroparesis, Idiopathic Gastroparesis
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
- Trial name
- NCT03281577
- Testing
- TAK-954
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Idiopathic Gastroparesis, Diabetic Gastroparesis
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT06836557
- Testing
- Tradipitant
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 17 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis
An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options
The purpose of this study is to assess the effectiveness of cisapride in patients with a primary diagnosis of chronic gastroparesis (a stomach disorder) of unknown cause.
- Trial name
- NCT01281540
- Testing
- Cisapride
- Volunteers
- 20 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.